BACKGROUND: A high multiple sclerosis activity while on alemtuzumab is rather uncommon compared to moderate-efficacy drugs. The purpose of this case report is to present a case of a 37-year-old female patient with bronchial asthma and no other medical history, whose disease activity required switching from dimethyl fumarate to fingolimod, then to alemtuzumab and finally to ocrelizumab. CASE PRESENTATION: In our patient, two severe attacks were observed and treated after administration of the first pulse of alemtuzumab. After six months of therapy, patient's immunological profile showed the expected decrease in CD4+ and CD8+ T-cells and, markedly increased values of CD19+ B-cells. Surprisingly memory B-cells, which typically repopulate very slowly following alemtuzumab treatment, were above baseline levels. Regular administration of ocrelizumab based on a standardised scheme, after the alemtuzumab therapy failure, resulted in the stabilisation of the patient's condition both clinically and radiologically. CONCLUSION: Thus, when the alemtuzumab treatment is unsuccessful, the authors recommend testing T- and B-cell levels and proceeding with an early switch to ocrelizumab if high B-cell counts are found.

Department of Neurology Faculty of Medicine and University Hospital Hradec Králové Charles University Prague 581 500 05 Hradec Králové Czech Republic

Department of Radiology University Hospital Hradec Králové Hradec Králové Czech Republic

Zobrazit více v PubMed

Miller JR. The importance of early diagnosis of multiple sclerosis. J Manag Care Pharm. 2004;10(3 Suppl B):S4–S11. PubMed

Kasper LH, Arnold DL, Cohen JA, Coles AJ, Fox EJ, Hartung HP. Lymphocyte subset dynamics following alemtuzumab treatment in CARE-MS II study. Presented at: 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis, Copenhagen, Denmark, 2–5 October 2013, P531.

Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. JAMA Neurol. 2017;74:961–969. doi: 10.1001/jamaneurol.2017.0676. PubMed DOI PMC

Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K. Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine. 2017;16:41–50. doi: 10.1016/j.ebiom.2017.01.042. PubMed DOI PMC

Akgün K, Blankenburg J, Marggraf M, Haase R, Ziemssen T. Event-driven immunoprofiling predicts return of disease activity in alemtuzumab-treated multiple sclerosis. Front Immunol. 2020;11:56. doi: 10.3389/fimmu.2020.00056. PubMed DOI PMC

Novi G, Fabbri S, Bovis F, Spragia E, Gazzola P, Maietta I, et al. Tailoring B-cells depleting therapy in MS according to memory B-cells monitoring: a pilot study. Presented at: 35th Congress of the European Committee for Research and Treatment in Multiple Sclerosis, Stockholm, Sweden, 11–13 September 2019, P971.

Lycke J. Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes. Ther Adv Neurol Disord. 2015;8:274–293. doi: 10.1177/1756285615605429. PubMed DOI PMC

Klein C, Lammens A, Schäfer W, Georges G, Schwaiger M, Mössner E, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013;5:22–33. doi: 10.4161/mabs.22771. PubMed DOI PMC

Rolla S, De Mercanti SF, Bardina V, Horakova D, Habek M, Adamec I, et al. Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses. J Neuroimmunol. 2017;313:89–91. doi: 10.1016/j.jneuroim.2017.10.009. PubMed DOI

Cossburn MD, Harding K, Ingram G, El-Shanawany T, Heaps A, Pickersgill TP, et al. Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. Neurology. 2013;80:55–61. doi: 10.1212/WNL.0b013e31827b5927. PubMed DOI

Kousin-Ezewu O, Azzopardi L, Parker RA, Tuohy O, Compston A, Coles A, et al. Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity. Neurology. 2014;82:2158–2164. doi: 10.1212/WNL.0000000000000520. PubMed DOI PMC

Wiendl H, Carraro M, Comi G, Izquierdo G, Kim HJ, Sharrack B, et al. Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab. Neurol Neuroimmunol Neuroinflamm. 2019;7:e635. doi: 10.1212/NXI.0000000000000635. PubMed DOI PMC

Identification of alemtuzumab-suitable multiple sclerosis patients in Slovakia and sequencing of post-alemtuzumab immunomodulatory treatment